Methotrexate; Pralatrexate/Probenecid Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process methotrexate or pralatrexate properly.
What might happen:
Your blood levels of methotrexate or pralatrexate may increase and cause easy bruising or bleeding, persistent sore throat or fever, or fatigue. These effects are more likely if you are taking a high dose of methotrexate, such as those used in the treatment of cancer or psoriasis.
What you should do about this interaction:
Contact your doctor as soon as possible if you are taking these two medicines. Your doctor may monitor your methotrexate or pralatrexate blood levels and the dosage may need to be adjusted.If you feel unusually drowsy, have blurred vision, headaches, stomach pain, fever, chills, rashes, mouth sores, nausea or vomiting, contact your doctor.Make sure that your doctor knows all of the medicines that you are taking. Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Israili ZH, Soliman AM, Cunningham RF, Plowden JF, Keller JW. The interaction of methotrexate and probenecid in man and dog. Proc Am Assoc Cancer Res 1978;19:194.
- 2.Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978 Apr 29;1(6120):1097-9.
- 3.Howell SB, Olshen RA, Rice JA. Effect of probenecid on cerebrospinal fluid methotrexate kinetics. Clin Pharmacol Ther 1979 Nov;26(5):641-6.
- 4.Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985; 15(3):220-2.
- 5.Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking low dose methotrexate and probenecid. J Rheumatol 1991 Apr; 18(4):609-10.
- 6.Folotyn (pralatrexate) US prescribing information. Allos Therapeutics, Inc. May, 2016.
- 7.Fury MG, Krug LM, Azzoli CG, Sharma S, Kemeny N, Wu N, Kris MG, Rizvi NA. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. Cancer Chemother Pharmacol 2006 May;57(5):671-7.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.